Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Single nucleotide Polymorphism
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Targeted Therapy
100%
Sunitinib
100%
Pharmacodynamic Biomarker
100%
Adverse Events
66%
MTOR Inhibitor
66%
Cytochrome P450 3A4 (CYP3A4)
50%
Hypertension
33%
Temsirolimus
33%
Everolimus
33%
Confidence Interval
16%
Kidney Tissue
16%
Odds Ratio
16%
Low Risk
16%
Large Cohort
16%
Pharmacokinetics
16%
Metabolism
16%
Logistic Regression Model
16%
Patient Well-being
16%
Polymorphism
16%
Statistical Analysis
16%
Clinical Factors
16%
Treatment Efficacy
16%
Patient Selection
16%
Drug Metabolism
16%
Measurement Analysis
16%
Germline DNA
16%
Pneumonitis
16%
Normal Kidney
16%
ATP Binding Cassette Subfamily B Member 1 (ABCB1)
16%
Toxicity Outcomes
16%
CYP3A5
16%
Three-core
16%
Rs1045642
16%
Core Genes
16%
CYP3A4 Polymorphism
16%
Medicine and Dentistry
Single Nucleotide Polymorphism
100%
Targeted Therapy
100%
Kidney Metastasis
100%
Sunitinib
100%
Pharmacogenomics
100%
Adverse Event
66%
Mammalian Target of Rapamycin Inhibitor
66%
CYP3A4
66%
Temsirolimus
33%
Everolimus
33%
Combination Therapy
16%
Logistic Regression Analysis
16%
Quality of Life
16%
Outcome Assessment
16%
Pharmacokinetics
16%
Drug Metabolism
16%
Kidney Tissue
16%
Cytochrome P450 3A5
16%
Germ Cell
16%
Odds Ratio
16%
Biochemistry, Genetics and Molecular Biology
Single-Nucleotide Polymorphism
100%
Pharmacogenomics
100%
Sunitinib
100%
Targeted Therapy
100%
Mammalian Target of Rapamycin
66%
CYP3A4
66%
Germline
16%
Germ Cell
16%
Pharmacokinetics
16%
Metabolic Pathway
16%
Candidate Gene
16%
Drug Metabolism
16%
CYP3A5
16%
Pharmacology, Toxicology and Pharmaceutical Science
Sunitinib
100%
Kidney Metastasis
100%
Pharmacogenomics
100%
Adverse Event
66%
Mammalian Target of Rapamycin Inhibitor
66%
CYP3A4
66%
Temsirolimus
33%
Everolimus
33%
Combination Therapy
16%
Drug Metabolism
16%
Cytochrome P450 3A5
16%
Pharmacokinetics
16%